Table 2.

Metabolite analysis in the participants.

	Control	HHcy	cblC-MMA
methylmalonic acid in urine (mmol/mmol creatinine)	0.00 (0.00–0.00)	0.00 (0.00–0.00)	0.74 (0.58–1.14)*&
HCY in serum (μmol/L)	5.44 (4.65–5.78)	89.70 (69.74–112.49) *	156.68 (150.07–171.08)*&
methylmalonic acid in serum (μmol/L)	0.05 (0.04–0.08)	0.06 (0.04–0.12)	5.73 (4.36–7.20)*&
C3 (μmol/L)	3.85 (3.10–4.34)	4.82 (3.48–7.06) *	7.28 (4.87–9.11)*
C0 (μmol/L)	27.4 (25.3–30.5)	25.3 (21.4–28.3)	17.60 (13.9–23.3)*&
C3/C0	0.14 (0.11–0.15)	0.22 (0.14–0.32) *	0.36 (0.25–0.56)*

^*p < 0.01 compared with control group;

^&p < 0.05 compared with HHcy group; HHcy, non-inherited hyperhomocysteinemia; MMA, methylmalonic acidemia; HCY, homocysteine; C3, propionylcarnitine; C0, free carnitine; C3/C0, the ratio of C3 and C0. Data were shown as median with 95% CI.